CN100516047C - 内酰胺化合物 - Google Patents

内酰胺化合物 Download PDF

Info

Publication number
CN100516047C
CN100516047C CNB018189962A CN01818996A CN100516047C CN 100516047 C CN100516047 C CN 100516047C CN B018189962 A CNB018189962 A CN B018189962A CN 01818996 A CN01818996 A CN 01818996A CN 100516047 C CN100516047 C CN 100516047C
Authority
CN
China
Prior art keywords
methyl
amino
compound
ketone
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018189962A
Other languages
English (en)
Chinese (zh)
Other versions
CN1575282A (zh
Inventor
T·M·柯尼
J·E·奥迪亚
D·米切尔
S·L·麦克丹尼尔
L·A·布茨利
G·L·恩格尔
J·A·埃金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1575282A publication Critical patent/CN1575282A/zh
Application granted granted Critical
Publication of CN100516047C publication Critical patent/CN100516047C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CNB018189962A 2000-11-17 2001-11-02 内酰胺化合物 Expired - Fee Related CN100516047C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
US60/249,656 2000-11-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910203885A Division CN101624372A (zh) 2000-11-17 2001-11-02 内酰胺化合物

Publications (2)

Publication Number Publication Date
CN1575282A CN1575282A (zh) 2005-02-02
CN100516047C true CN100516047C (zh) 2009-07-22

Family

ID=22944436

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018189962A Expired - Fee Related CN100516047C (zh) 2000-11-17 2001-11-02 内酰胺化合物
CN200910203885A Pending CN101624372A (zh) 2000-11-17 2001-11-02 内酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910203885A Pending CN101624372A (zh) 2000-11-17 2001-11-02 内酰胺化合物

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN100516047C (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2002224321B2 (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2413705T3 (es) 2005-04-08 2013-07-17 Daiichi Sankyo Company, Limited Derivado de piridilmetilsulfona
JP5198877B2 (ja) 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2021195362A1 (en) 2020-03-26 2021-09-30 Seagen Inc. Methods of treating multiple myeloma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242007A (zh) * 1996-12-23 2000-01-19 伊兰药品公司 环烷基、内酰胺、内酯和相关化合物、包括这些化合物的药用组合物以及用这些化合抑制β淀粉样肽释放和/或其合成的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242007A (zh) * 1996-12-23 2000-01-19 伊兰药品公司 环烷基、内酰胺、内酯和相关化合物、包括这些化合物的药用组合物以及用这些化合抑制β淀粉样肽释放和/或其合成的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REIFFEN M ET AL.JOURNAL OR MEDICIN AL CHEMISTRY,Vol.33 No.5. 1990 *

Also Published As

Publication number Publication date
JP4116431B2 (ja) 2008-07-09
AU2002224321B2 (en) 2006-10-19
HUP0301862A2 (hu) 2003-09-29
WO2002040451A2 (en) 2002-05-23
WO2002040451A3 (en) 2003-08-28
ECSP034598A (es) 2003-06-25
TWI235151B (en) 2005-07-01
DE60128587D1 (de) 2007-07-05
DK1353910T3 (da) 2007-09-10
DE60128587T2 (de) 2008-01-31
CY1106682T1 (el) 2012-05-23
CN1575282A (zh) 2005-02-02
ATE362919T1 (de) 2007-06-15
DZ3454A1 (fr) 2002-05-23
US20040248878A1 (en) 2004-12-09
EP1353910A2 (en) 2003-10-22
JP2004521084A (ja) 2004-07-15
CZ20031340A3 (cs) 2004-06-16
SK5432003A3 (en) 2004-09-08
CA2425497A1 (en) 2002-05-23
CA2425497C (en) 2010-08-17
HRP20030385A2 (en) 2003-08-31
MY141607A (en) 2010-05-31
ZA200303411B (en) 2004-08-02
SV2003000741A (es) 2003-01-13
EP1353910B1 (en) 2007-05-23
SK287794B6 (sk) 2011-10-04
CN101624372A (zh) 2010-01-13
HUP0301862A3 (en) 2007-09-28
NO20032215D0 (no) 2003-05-15
NO325217B1 (no) 2008-02-25
PE20020798A1 (es) 2002-09-06
MXPA03004250A (es) 2003-09-22
AU2432102A (en) 2002-05-27
IL155275A0 (en) 2003-11-23
KR20030045194A (ko) 2003-06-09
ES2286162T3 (es) 2007-12-01
UA77165C2 (en) 2006-11-15
AR031356A1 (es) 2003-09-17
NO20032215L (no) 2003-07-16
PL211018B1 (pl) 2012-03-30
PT1353910E (pt) 2007-08-20
BR0115424A (pt) 2003-10-21
EA200300579A1 (ru) 2003-12-25
EA006919B1 (ru) 2006-04-28
PL360991A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
CN100516047C (zh) 内酰胺化合物
TWI404537B (zh) 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
CA3115609C (en) Processes of making and crystalline forms of a mdm2 inhibitor
CZ20031351A3 (cs) Laktamová sloučenina pro inhibici uvolňování nebo syntézy beta-amyloidového peptidu
JP2017105816A (ja) （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）スルファミン酸メチルの塩酸塩
AU2002224321A1 (en) Lactam compound
JP2004521084A5 (enExample)
CN116783183B (zh) 用于治疗贫血和癌症的vhl抑制剂
TWI899051B (zh) 二氫唏衍生物
CN110372557B (zh) 环己烷胺类d3/d2受体部分激动剂
EP1838716B1 (en) Olanzapine pamoate dihydrate
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
ES2311561T3 (es) Dipeptido de lactama y su uso en la inhibicion de la liberacion del peptido beta amiloide.
CN100554247C (zh) 毒蕈碱激动剂
US20040077627A1 (en) Lactam compound
HK40092810A (zh) 作为vhl抑制剂用於治疗贫血和癌症的1-(2-(4-环丙基-1h-1，2，3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
HK1220691A1 (zh) 用作卵泡刺激素受体调节剂的咪唑化合物及其用途
HK1226052B (en) Crystalline form of a mdm2 inhibitor
HK1226052A1 (en) Crystalline form of a mdm2 inhibitor
NZ525365A (en) Lactam compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090722

Termination date: 20141102

EXPY Termination of patent right or utility model